In The News

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Dr. David Reardon discusses the efficacy of two immunotherapy combinations for Glioblastoma.

    discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
    David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpufDr. D

Tags: BrainTumors

  • Dr. Nikhil Wagle led a study showing how the Internet can help recruit patients for breast cancer research.

     

Tags: BreastCancer

  • Dr. Eric Winer led a study showing women with early-stage breast cancer could benefit from taking an estrogen-suppressing drug for 10 years rather than the standard five.

Tags: BreastCancer

  • Dr. Stuart Orkin talks about plans to cut costs concerning gene therapies.

Tags: ChildhoodCancer

  • Dr. Geoffrey Oxnard is profiled along with one of his patients concerning targeted therapies to treat lung cancer.

Tags: LungCancer, TargetedTherapy

  • Dr. F. Stephen Hodi helped lead research showing the cancer drug Keytruda has helped about 40 percent of melanoma patients survive longer.

Tags: Melanoma

  • Dr. Jeffrey Meyerhardt helped lead research showing the location of a patient’s colon cancer may predict survival outcomes.

     

Tags: ColonCancer

  • Nurse Joan Lucca comments on working with the Stand Up To Cancer Research Institute Immunology Dream Team.

Tags: Nursing

  • Dr. Jay Harris commented on a study showing extreme breath-holding like that practiced by free divers may have usefulness in treating patients.

Tags: Radiation

  • Dr. Deborah Schrag wrote an editorial for JAMA talking about the need for more treatments for Pancreatic Cancer.

Tags: PancreaticCancer

Showing 11-20 of 674 items